Reviewed by: Methylene Blue Ultra Science Team
150 Years of Medical History

History of Methylene Blue

From a German dye factory in 1876 to modern longevity research — the remarkable 150-year journey of the world's first fully synthetic drug. Nobel Prizes, WHO recognition, and a new chapter in cognitive science.

1876First Synthesis
150+Years Medical Use
171Clinical Trials
Timeline1876 - 2026
Discovery Era (1876-1890)
Malaria Era (1891-1950)
Medical Era (1950-2000)
Cognitive Era (2000-Present)

150 Years of Methylene Blue

1876
Discovery Era

First Synthesis at BASF

Heinrich Caro synthesizes methylene blue at BASF in Ludwigshafen, Germany. It becomes the world's first fully synthetic drug and the first synthetic textile dye.[1]

1882
Discovery Era

Robert Koch Uses MB as Stain

Robert Koch uses methylene blue to stain the tuberculosis bacillus, enabling visualization of bacteria under microscopy. This technique revolutionizes microbiology.

1886
Discovery Era

Paul Ehrlich's Selective Staining

Paul Ehrlich discovers that methylene blue selectively stains nerve tissue and parasites. This observation leads to the concept of 'magic bullets' in pharmacology.[1]

1891
Malaria Era

First Antimalarial Treatment

Paul Ehrlich and Paul Guttmann treat two malaria patients with methylene blue — the first synthetic antimalarial drug. This marks the birth of chemotherapy.

1908
Malaria Era

Ehrlich Nobel Prize

Paul Ehrlich receives the Nobel Prize in Physiology or Medicine. His work on methylene blue's selective affinity for tissues laid the foundation for targeted drug therapy.[1]

1920
Malaria Era

Urinary Antiseptic Use

Methylene blue gains widespread use as a urinary tract antiseptic. Its blue coloration of urine becomes a well-known side effect.

1933
Medical Era

Methemoglobinemia Antidote

First documented use of methylene blue as an antidote for methemoglobinemia, where it reduces methemoglobin back to hemoglobin. This remains an FDA-approved use today.

1940
Malaria Era

Chloroquine Replaces MB

Chloroquine and other synthetic antimalarials replace methylene blue for malaria treatment due to lower dosing requirements and fewer side effects.

1960
Medical Era

Surgical Dye Applications

Methylene blue becomes widely used as a surgical dye for identifying tissues, detecting fistulas, and marking sentinel lymph nodes in cancer surgery.

1978
Medical Era

Vasoplegic Syndrome Treatment

Researchers discover methylene blue's effectiveness in treating vasoplegic syndrome during cardiac surgery by inhibiting nitric oxide pathways.

1996
Cognitive Era

Tau Aggregation Inhibitor

Claude Wischik identifies methylene blue as a potent inhibitor of tau protein aggregation in Alzheimer's disease, opening a new chapter in neurodegenerative research.[3]

2004
Cognitive Era

Fear Extinction Studies

Gonzalez-Lima publishes research showing methylene blue enhances fear extinction memory in rats, suggesting cognitive enhancement potential.[5]

2011
Cognitive Era

FDA Black Box Warning

FDA adds black box warning about serotonin syndrome risk when methylene blue is combined with serotonergic drugs (SSRIs, MAOIs). This interaction was previously unknown.

2013
Cognitive Era

Neuroprotective Mechanisms

Research establishes methylene blue's role as an alternative electron carrier in mitochondria, bypassing damaged Complex I and III to maintain ATP production.

2016
Cognitive Era

Human fMRI Cognitive Study

Rodriguez et al. publish randomized controlled fMRI study showing methylene blue improves sustained attention and memory in healthy humans.[4]

2018
Cognitive Era

Sepsis Mortality Research

Multiple studies investigate methylene blue for septic shock, showing potential mortality reduction through nitric oxide inhibition and mitochondrial support.

2020
Cognitive Era

COVID-19 Investigation

Researchers explore methylene blue as potential COVID-19 treatment due to its antiviral properties and effect on inflammatory pathways. Results are mixed.

2022
Cognitive Era

WHO Essential Medicines List

Methylene blue remains on the WHO Model List of Essential Medicines as an antidote for methemoglobinemia and ifosfamide-induced encephalopathy.

2024
Cognitive Era

Biohacking Community Adoption

Methylene blue gains significant traction in the biohacking and longevity community. Podcasters and researchers promote its cognitive and mitochondrial benefits.

2026
Cognitive Era

MB Ultra Launch

Methylene Blue Ultra launches as the first MB supplement with integrated biomarker tracking via epigenetic age testing, enabling users to measure outcomes objectively.

Frequently Asked Questions

When was methylene blue first synthesized?

Methylene blue was first synthesized in 1876 by Heinrich Caro at BASF in Ludwigshafen, Germany. It was the world's first fully synthetic drug and the first synthetic textile dye, marking a revolution in both medicine and chemistry.

Who discovered methylene blue's medical uses?

Paul Ehrlich discovered methylene blue's selective affinity for tissues and parasites in the 1880s. In 1891, Ehrlich and Paul Guttmann used methylene blue to treat malaria patients — the first use of a synthetic drug against an infectious disease. Ehrlich received the Nobel Prize in 1908.

Why did methylene blue fall out of use for malaria?

Methylene blue was largely replaced by chloroquine and other synthetic antimalarials in the 1940s. These newer drugs required lower doses and had fewer side effects (like blue urine). However, methylene blue is being reconsidered as chloroquine resistance increases globally.

Is methylene blue still used medically today?

Yes. Methylene blue is FDA-approved as an antidote for methemoglobinemia and ifosfamide-induced encephalopathy. It remains on the WHO Model List of Essential Medicines. It's also used as a surgical dye and is under investigation for cognitive enhancement and neuroprotection.

When did cognitive research on methylene blue begin?

Modern cognitive research on methylene blue began in the 2000s. Key milestones include Gonzalez-Lima's 2004 fear extinction studies, Wischik's tau aggregation research (1996), and Rodriguez's 2016 fMRI study showing improved attention and memory in healthy humans.

Related Pages

ResearchMB Science →ResearchResearch Hub →Modern AlternativesBrand Comparison →ReferenceGlossary →

References

  1. [1]Schirmer RH, Adler H, Pickhardt M, et al. (2011). Lest we forget you — methylene blue. Neurobiology of Aging. PMC3178874
  2. [2]Oz M, Lorke DE, Petroianu GA (2009). Methylene blue and Alzheimer's disease. Biochemical Pharmacology. PMC3087269
  3. [3]Wischik CM, Edwards PC, Lai RY, et al. (1996). Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proceedings of the National Academy of Sciences. 10.1073/pnas.93.20.11213
  4. [4]Rodriguez P, Zhou W, Barrett DW, et al. (2016). Multimodal randomized functional MR imaging of the effects of methylene blue in the human brain. Radiology. PMC5207111
  5. [5]Gonzalez-Lima F, Bruchey AK (2004). Extinction memory improvement by the metabolic enhancer methylene blue. Learning & Memory. PMC534699